AT
KPTI icon

American Trust’s Karyopharm Therapeutics KPTI Stock Holding History

American Trust’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-781
Closed -$64K – 464
2022
Q3 		$64K Sell
781
-14
-2% -$1.05K 0.01% 413
2022
Q2 		$54K Sell
795
-31
-4% -$2.84K ﹤0.01% 438
2022
Q1 		$91K Sell
826
-11
-1% -$1.37K 0.01% 497
2021
Q4 		$81K Buy
+837
New +$83.4K 0.01% 369

Other funds holding KPTI

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

American Trust's KPTI Position: Q4 2022 in Review

American Trust sold out of Karyopharm Therapeutics (KPTI) in Q4 2022, closing a stake of 781 shares — an estimated $64K sold.

American Trust first reported a position in KPTI in Q4 2021 and held it in 4 quarters. The position peaked at $91K in Q1 2022. 154 funds tracked by Wall St. Rank hold KPTI as of Q4 2022.

  • American Trust reported no remaining Karyopharm Therapeutics position as of Q4 2022 after selling out during the quarter.
  • American Trust sold 781 Karyopharm Therapeutics shares in Q4 2022, an estimated $64K.
  • American Trust first reported a position in Karyopharm Therapeutics in Q4 2021 and held it in 4 quarters.
  • American Trust's Karyopharm Therapeutics position peaked at $91K in Q1 2022.
  • 154 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2022.

Based on American Trust's 13F filing for Q4 2022, filed 16 Feb 2023.